Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Marlon C. Rebelatto"'
Autor:
Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon C. Rebelatto, Jill Walker
Publikováno v:
Diagnostic Pathology, Vol 14, Iss 1, Pp 1-10 (2019)
Abstract Background Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been inve
Externí odkaz:
https://doaj.org/article/4877dc5bab8d486eb643d9fe5d131069
Autor:
Paul Scorer, Marietta Scott, Nicola Lawson, Marianne J. Ratcliffe, Craig Barker, Marlon C. Rebelatto, Jill Walker
Publikováno v:
Diagnostic Pathology, Vol 13, Iss 1, Pp 1-10 (2018)
Abstract Background Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) therapies have shown encouraging safety and clinical activity in a variety of tumor types. A potential role for PD-L1 testing in identifyi
Externí odkaz:
https://doaj.org/article/43ffde86cf27475dba967a42ba02277c
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019)
BackgroundImmune checkpoint therapies (ICTs) targeting the programmed cell death-1 (PD1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes for patients with non-small cell lung cancer (NSCLC), particularly those with high PD-L1 ex
Externí odkaz:
https://doaj.org/article/4d5cf4fc12e749baa959d36611030a85
Autor:
Jill Walker, Marlon C. Rebelatto, Hytham Al-Masri, Paul Scorer, Marietta Scott, Craig Barker, Anita Midha, Alan Sharpe, Marianne J. Ratcliffe
Supplementary Table S1. Comparison of PD-L1 diagnostic assays for patients with NSCLC Supplementary Table S2. Detailed scoring criteria for each assay in the study Supplementary Table S3. Demographics of patients who provided study samples Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07aacfa0b54063413c092e13aaeca054
https://doi.org/10.1158/1078-0432.22466039
https://doi.org/10.1158/1078-0432.22466039
Autor:
David A. Tice, Philip W. Howard, Ronald Herbst, Kenneth C. Anderson, Luke Masterson, Michael J. Wick, Stephen J. Gregson, Sriram Sridhar, Kyriakos P. Papadopoulos, Alyssa Moriarty, Nazzareno Dimasi, Marlon C. Rebelatto, Christine Mione Kiefer, Sandrina Phipps, Yu-Tzu Tai, Arnaud C. Tiberghien, John Meekin, Krista Kinneer
Purpose:Antibody–drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clinical use, and several are in development targeting solid and hematologic malignancies including multiple myeloma. Currently, there are no reliable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80839c279aab8bddbee384f0cdadbd2b
https://doi.org/10.1158/1078-0432.c.6527396.v1
https://doi.org/10.1158/1078-0432.c.6527396.v1
Autor:
Jill Walker, Marlon C. Rebelatto, Hytham Al-Masri, Paul Scorer, Marietta Scott, Craig Barker, Anita Midha, Alan Sharpe, Marianne J. Ratcliffe
Purpose: Immunotherapies targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) demonstrate encouraging antitumor activity and manageable tolerability in non–small cell lung cancer (NSCLC), especially in patients with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac6ca4005b4ba30e410ab5f659432998
https://doi.org/10.1158/1078-0432.c.6526226
https://doi.org/10.1158/1078-0432.c.6526226
Autor:
David A. Tice, Philip W. Howard, Ronald Herbst, Kenneth C. Anderson, Luke Masterson, Michael J. Wick, Stephen J. Gregson, Sriram Sridhar, Kyriakos P. Papadopoulos, Alyssa Moriarty, Nazzareno Dimasi, Marlon C. Rebelatto, Christine Mione Kiefer, Sandrina Phipps, Yu-Tzu Tai, Arnaud C. Tiberghien, John Meekin, Krista Kinneer
Supplementary methods and materials, and Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f906385187323fe823fa7c557d5fdaf
https://doi.org/10.1158/1078-0432.22469939
https://doi.org/10.1158/1078-0432.22469939
Autor:
David A. Tice, Philip W. Howard, Ronald Herbst, Kenneth C. Anderson, Luke Masterson, Michael J. Wick, Stephen J. Gregson, Sriram Sridhar, Kyriakos P. Papadopoulos, Alyssa Moriarty, Nazzareno Dimasi, Marlon C. Rebelatto, Christine Mione Kiefer, Sandrina Phipps, Yu-Tzu Tai, Arnaud C. Tiberghien, John Meekin, Krista Kinneer
Supplementary table showing the relative expression of 43 target genes in a panel of EphA2-positive cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::656bb05d0a44970a8add94d9221308b0
https://doi.org/10.1158/1078-0432.22469936.v1
https://doi.org/10.1158/1078-0432.22469936.v1
Autor:
Do-Youn Oh, Kyung-Hun Lee, Dae-Won Lee, Jeesun Yoon, Tae-Yong Kim, Ju-Hee Bang, Ah-Rong Nam, Kyoung-Seok Oh, Jae-Min Kim, Young Lee, Violeta Guthrie, Patricia McCoon, Weimin Li, Song Wu, Qu Zhang, Marlon C Rebelatto, Jin Won Kim
Publikováno v:
The lancet. Gastroenterologyhepatology. 7(6)
Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52642afd625545543cdfcae88b470959
https://pubmed.ncbi.nlm.nih.gov/35278357
https://pubmed.ncbi.nlm.nih.gov/35278357
Autor:
Ignacio I Wistuba, Michael T Tetzlaff, Carlo B Bifulco, Katharina von Loga, Sacha Gnjatic, Scott J Rodig, Keith E Steele, Marlon C Rebelatto, Ana Lako, Guray Akturk, Michael Angelo, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Jonathan Juco, Jaime Rodriguez-Canales, Kurt A Schalper, Edward C Stack, Cláudia S Ferreira, Konstanty Korski, Emanuel Schenck, Michael J Surace
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::7bf3be5d1fede6e6cdd97ba97f9f858b
https://jitc.bmj.com/content/8/1/e000325corr1.full
https://jitc.bmj.com/content/8/1/e000325corr1.full